Selmod develops selective mode antimicrobial resistance therapeutics, focusing on small molecules and peptides that target multi-drug resistant fungal and bacterial infections. The company aims to provide effective treatment options for life-threatening infections that are unresponsive to existing antibiotics.
Funding
$80K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Multi-drug resistant fungal and bacterial infections pose a significant threat, often proving unresponsive to existing antibiotics and leading to life-threatening conditions. The limited availability of effective treatment options exacerbates the challenge of combating these infections.
Solution
Selmod is developing selective mode antimicrobial resistance therapeutics, focusing on innovative small molecules and peptides designed to combat multi-drug resistant infections. Their approach centers on discovering and developing novel antibiotics that target new targets or employ new mechanisms of action on established targets. By focusing on these innovative approaches, Selmod aims to provide effective treatment options for life-threatening infections that are resistant to current antibiotics. This involves rigorous discovery and early clinical development to ensure the efficacy and safety of their therapeutics.
Target Audience
The primary target audience includes patients suffering from life-threatening, multi-drug resistant fungal and bacterial infections, as well as healthcare providers seeking effective treatment options for these infections.
Features
- Focus on small molecule and peptide-based therapeutics.
- Targeting of new antimicrobial targets.
- Development of new mechanisms of action against validated targets.
- Addressing multi-drug resistant fungal infections.
- Addressing multi-drug resistant bacterial infections.